Last checked at 23 Jan 2020 15:06
Hutchison China Prices USD110 Million American Depositary Share Offer
Hutchison China Prices USD110 Million American Depositary Share Offer
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Hutchmed Share News (HCM)
HCM Share
Price
HCM Share
News
HCM Share
Chat
HCM Share
Trades53
HCM
Live RNS
HCM Share
Charts
HCM Level 2
Console
HCM Live
Share Price
HCM Broker
Ratings
HCM Directors
Deals
HCM Financial
Diary
HCM
Fundamentals
HCM Short
Positions
HCM
Media
Hutchmed Information
Share Price Information for Hutchmed (HCM)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
300.00
Bid:
299.00
Ask:
300.00
Change:
2.50 (0.84%)
Spread:
1.00 (0.334%)
Open:
292.00
High:
303.00
Low:
292.00
Prev. Close:
297.50
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.22 Jan 2020 10:44
Hutchison China Plans USD110 Million American Depositary Share Offer
Hutchison China Plans USD110 Million American Depositary Share Offer
Read more20 Jan 2020 16:00
Hutchison Chi-Med upbeat on progress with surufatinib
(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, announced on Friday that the independent data monitoring committee of the phase 3 pivotal study of surufatinib in advanced neuroendocrine tumours - pancreatic (SANET-p) has completed a pre-planned interim analysis.
Read more20 Jan 2020 11:37
Hutchinson China Reports Early Success Of Surufatinib Phase III Study
Hutchinson China Reports Early Success Of Surufatinib Phase III Study
Read more13 Jan 2020 09:01
Hutchison China Starts Phase II Study For Cancer Treatment In China
Hutchison China Starts Phase II Study For Cancer Treatment In China
Read more20 Dec 2019 15:48
Hutchison Chi-Med gets priority review for 'surufatinib' in China
(Sharecast News) - Hutchison China MediTech announced on Friday that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted 'Priority Review' status to its new drug application for 'surufatinib', for the treatment of patients with advanced non-pancreatic neuroendocrine tumours.
Read more20 Dec 2019 12:10
Hutchison China Hails "Positive Step" For Cancer Treatment In China
Hutchison China Hails "Positive Step" For Cancer Treatment In China
Read more28 Nov 2019 14:58
Hutchison China MediTech's Cancer Treatment Joins Key China State List
Hutchison China MediTech's Cancer Treatment Joins Key China State List
Read more25 Nov 2019 13:47
Hutchison China MediTech Gets Orphan Designation For Surufatinib
Hutchison China MediTech Gets Orphan Designation For Surufatinib
Read more12 Nov 2019 12:19
CORRECT (Nov 11): Hutchison's Surufatinib Gets Acceptance For Review
CORRECT (Nov 11): Hutchison's Surufatinib Gets Acceptance For Review
Read more11 Nov 2019 11:08
Hutchison's Surufatinib Gets New Drug Application Approval In China
Hutchison's Surufatinib Gets New Drug Application Approval In China
Read more10 Oct 2019 15:45
Hutchison China Meditech expands collaboration with Innovent
(Sharecast News) - Hutchison China Meditech on Thursday confirmed the expansion of its tumour treatment collaboration agreement with Innovent Biologics Inc..
Read more10 Oct 2019 12:43
Hutchison China Expands Tumour Treatment Collaboration With Innovent
Hutchison China Expands Tumour Treatment Collaboration With Innovent
Read more4 Oct 2019 15:21
Hutchison Chi-Med initiates latest study of HMPL-523
(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, has initiated an international phase 1 and 1b study of 'HMPL-523' - its novel spleen tyrosine kinase inhibitor - in patients with relapsed or refractory lymphoma, it announced on Friday.
Read more4 Oct 2019 10:26
WINNERS & LOSERS SUMMARY: Astra Rises On Fasenra Approval In US
WINNERS & LOSERS SUMMARY: Astra Rises On Fasenra Approval In US
Read more